Last reviewed · How we verify

Myxedema coma — Treatment Landscape & Competitive Intelligence

Myxedema coma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myxedema coma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Triostat LIOTHYRONINE Pfizer l-Triiodothyronine Thyroid hormone receptor alpha 1956-01-01
Triiodothyronine Triiodothyronine Northwell Health THAP domain-containing protein 1, Cytochrome P450 2C9, Proliferating cell nuclear antigen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Northwell Health · 1 drug in Myxedema coma
  2. Pfizer · 1 drug in Myxedema coma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myxedema coma:

Cite this brief

Drug Landscape (2026). Myxedema coma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myxedema-coma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing